These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25459760)

  • 21. Elucidating substrate promiscuity in the human cytochrome 3A4.
    Hayes C; Ansbro D; Kontoyianni M
    J Chem Inf Model; 2014 Mar; 54(3):857-69. PubMed ID: 24571781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation.
    He XY; Shen J; Hu WY; Ding X; Lu AY; Hong JY
    Arch Biochem Biophys; 2004 Jul; 427(2):143-53. PubMed ID: 15196988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamics and hydration of the active sites of mammalian cytochromes P450 probed by molecular dynamics simulations.
    Hendrychova T; Berka K; Navratilova V; Anzenbacher P; Otyepka M
    Curr Drug Metab; 2012 Feb; 13(2):177-89. PubMed ID: 22208532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural and dynamical aspects of Streptococcus gordonii FabH through molecular docking and MD simulations.
    Shamim A; Abbasi SW; Azam SS
    J Mol Graph Model; 2015 Jul; 60():180-96. PubMed ID: 26059477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK.
    Xu Y; Shen Z; Shen J; Liu G; Li W; Tang Y
    J Mol Graph Model; 2011 Sep; 30():1-9. PubMed ID: 21680215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suitability of MMGBSA for the selection of correct ligand binding modes from docking results.
    Ahinko M; Niinivehmas S; Jokinen E; Pentikäinen OT
    Chem Biol Drug Des; 2019 Apr; 93(4):522-538. PubMed ID: 30468569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism of bilirubin by human cytochrome P450 2A6.
    Abu-Bakar A; Arthur DM; Wikman AS; Rahnasto M; Juvonen RO; Vepsäläinen J; Raunio H; Ng JC; Lang MA
    Toxicol Appl Pharmacol; 2012 May; 261(1):50-8. PubMed ID: 22465937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting the binding modes and sites of metabolism of xenobiotics.
    Mukherjee G; Lal Gupta P; Jayaram B
    Mol Biosyst; 2015 Jul; 11(7):1914-24. PubMed ID: 25913019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
    Bello M; Mendieta-Wejebe JE; Correa-Basurto J
    Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Site of metabolism prediction for oxidation reactions mediated by oxidoreductases based on chemical bond.
    He S; Li M; Ye X; Wang H; Yu W; He W; Wang Y; Qiao Y
    Bioinformatics; 2017 Feb; 33(3):363-372. PubMed ID: 27667794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study.
    Gadhe CG; Balupuri A; Cho SJ
    J Biomol Struct Dyn; 2015; 33(11):2491-510. PubMed ID: 25617117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
    Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
    Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling loop backbone flexibility in receptor-ligand docking simulations.
    Flick J; Tristram F; Wenzel W
    J Comput Chem; 2012 Dec; 33(31):2504-15. PubMed ID: 22886372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simulation of carbohydrates, from molecular docking to dynamics in water.
    Sapay N; Nurisso A; Imberty A
    Methods Mol Biol; 2013; 924():469-83. PubMed ID: 23034760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PreMetabo: An in silico phase I and II drug metabolism prediction platform.
    Hwang S; Shin HK; Shin SE; Seo M; Jeon HN; Yim DE; Kim DH; No KT
    Drug Metab Pharmacokinet; 2020 Aug; 35(4):361-367. PubMed ID: 32616370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity.
    Yadav IS; Nandekar PP; Srivastavaa S; Sangamwar A; Chaudhury A; Agarwal SM
    Gene; 2014 Apr; 539(1):82-90. PubMed ID: 24491504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors.
    Kong X; Pan P; Li D; Tian S; Li Y; Hou T
    Phys Chem Chem Phys; 2015 Feb; 17(8):6098-113. PubMed ID: 25644934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
    Messina ES; Tyndale RF; Sellers EM
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the challenges of protein flexibility in drug design.
    Antunes DA; Devaurs D; Kavraki LE
    Expert Opin Drug Discov; 2015 Dec; 10(12):1301-13. PubMed ID: 26414598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of cytochrome P450 mediated metabolism.
    Olsen L; Oostenbrink C; Jørgensen FS
    Adv Drug Deliv Rev; 2015 Jun; 86():61-71. PubMed ID: 25958010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.